Selpercatinib Approved for First-Line Treatment of RET-Mutant Non-Small Cell Lung Cancer
Table of Contents
On September 16,2025,the U.S. food and Drug Administration (FDA) announced the approval of selpercatinib (Retevmo) as a first-line treatment option for patients with RET-mutant non-small cell lung cancer (NSCLC). This approval marks a important advancement in the treatment of this specific subtype of lung cancer,offering a targeted therapy option before the use of chemotherapy.
Understanding RET-Mutant NSCLC
Non-small cell lung cancer is the most common type of lung cancer,accounting for 80-85% of all cases. Within NSCLC, a subset of patients harbor alterations in the RET gene. These alterations, which include mutations, fusions, and rearrangements, drive cancer growth. RET (Rearranged during transfection) is a gene that provides instructions for making a protein that is involved in normal cell growth and growth. When RET is altered, it can lead to uncontrolled cell proliferation and tumor formation.
How Selpercatinib Works
Selpercatinib is a highly selective and potent RET inhibitor. this means it specifically targets and blocks the activity of the abnormal RET protein produced by RET alterations. By inhibiting RET, selpercatinib can slow or stop the growth of cancer cells. It is an oral medication, offering a convenient administration route for patients.
Clinical Trial Results Supporting the Approval
The FDA approval is based on data from the Phase 3 LIBRETTO-001 trial. This trial demonstrated that selpercatinib significantly improved progression-free survival (PFS) compared to standard platinum-based chemotherapy in patients with advanced RET-mutant NSCLC. Specifically, patients treated with selpercatinib experienced a median PFS of 22.1 months versus 4.3 months with chemotherapy. The objective response rate (ORR) was also significantly higher in the selpercatinib arm (64% vs. 29%).
Key Findings from LIBRETTO-001
- Progression-Free Survival (PFS): Selpercatinib demonstrated a statistically significant improvement in PFS compared to chemotherapy.
- Objective Response Rate (ORR): A higher percentage of patients responded to selpercatinib compared to chemotherapy.
- Safety Profile: Selpercatinib generally had a manageable safety profile, with common side effects including hypertension, edema, and fatigue.
Implications for Patients
This approval provides a new, targeted treatment option for patients with RET-mutant NSCLC, potentially improving their outcomes and quality of life. Prior to this approval,chemotherapy was the standard first-line treatment. Identifying RET alterations through complete genomic testing is crucial to determine if a patient is eligible for selpercatinib therapy.
Future directions
Research continues to explore the potential of selpercatinib in other cancers with RET alterations, including thyroid cancer and other solid tumors. Further studies are also underway to investigate combination therapies involving selpercatinib to enhance it’s efficacy and overcome potential resistance mechanisms.The approval of selpercatinib represents a significant step forward in personalized cancer treatment, highlighting the importance of genomic testing and targeted therapies.
Publication Date: 2025/09/16 11:19:47